Incretin Atlas › Trials › TRIUMPH-1-OSA / TRIUMPH-2-OSA
TRIUMPH-1-OSA / TRIUMPH-2-OSA
Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D)
Design
- Molecule(s)
- Retatrutide
- Population
- Obstructive sleep apnoea + obesity (with or without T2D)
- Participants
- 691
- Duration
- 80 weeks
Outcomes in the indication
TRIUMPH-1-OSA / TRIUMPH-2-OSA Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D) · 80 weeks · n = 691 verified
AHI −24.4 (9 mg) and −21.9 (12 mg) events/h vs placebo without T2D; −14.4 and −15.1 with T2D (hybrid estimand, primary). Sub-studies nested in TRIUMPH-1 and TRIUMPH-2.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 4 mg week 80 | −22.9 | −9.9 | −13.0 (−23.0 to −3.0) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 9 mg week 80 | −34.3 | −9.9 | −24.4 (−34.1 to −14.7) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 12 mg week 80 | −31.7 | −9.9 | −21.9 (−32.2 to −11.5) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 4 mg week 80 | −19.2 | −10.3 | −8.9 (−15.9 to −2.0) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 9 mg week 80 | −24.7 | −10.3 | −14.4 (−21.6 to −7.2) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 12 mg week 80 | −25.4 | −10.3 | −15.1 (−22.5 to −7.7) events/h | verified |
Verbatim quotes (6)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−22.9 (−29.7 to −16.0)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−34.3 (−40.8 to −27.7)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−31.7 (−38.2 to −25.2)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−19.2 (−23.7 to −14.7)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−24.7 (−29.9 to −19.5)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−25.4 (−30.6 to −20.1)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRIUMPH-1-OSA / TRIUMPH-2-OSA. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1-osa-triumph-2-osa/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.